Loading...

Weidhaas, Joanne B

Title(s)Professor, Radiation Oncology
Phone310-825-8278
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibition
    NIH/NCI R01CA238998May 1, 2019 - Apr 30, 2024
    Role: Principal Investigator
    MicroRNAs to Understand Cause and Outcome in Breast Cancer
    NIH/NCI R01CA157749Jul 1, 2012 - May 31, 2017
    Role: Principal Investigator
    Let-7 microRNAs in Lung Cancer: Altering Growth and Radioresistance
    NIH/NCI R01CA131301Mar 5, 2009 - Jan 31, 2014
    Role: Principal Investigator
    Defining the Genetic Basis of the Radioresponse Using a C. elegans Tissue Model
    NIH/NCI K08CA124484Sep 18, 2007 - Aug 31, 2012
    Role: Principal Investigator
    The UCLA Center for Medical Countermeasures Against Radiation
    NIH/NIAID U19AI067769Aug 31, 2005 - Jul 31, 2020
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Kalbasi A, Kamrava M, Chu FI, Telesca D, Van Dams R, Yang Y, Ruan D, Nelson SD, Dry S, Hernandez J, Chmielowski B, Singh AS, Bukata SV, Bernthal N, Steinberg ML, Weidhaas JB, Eilber FC. A Phase 2 Trial of Five-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma. Clin Cancer Res. 2020 Feb 13. PMID: 32054730.
      View in: PubMed
    2. Weidhaas JB. Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy. Methods Mol Biol. 2020; 2055:203-212. PMID: 31502153.
      View in: PubMed
    3. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 Jul 04; 7(1):167. PMID: 31272507.
      View in: PubMed
    4. D'Hooghe TM, Grechukhina O, Cho S, Fassbender A, O D, Peterse D, Weidhaas J, Taylor HS. Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study. Gynecol Obstet Invest. 2019; 84(6):575-582. PMID: 31185482.
      View in: PubMed
    5. Vapiwala N, Thomas CR, Grover S, Yap ML, Mitin T, Shulman LN, Gospodarowicz MK, Longo J, Petereit DG, Ennis RD, Hayman JA, Rodin D, Buchsbaum JC, Vikram B, Abdel-Wahab M, Epstein AH, Okunieff P, Goldwein J, Kupelian P, Weidhaas JB, Tucker MA, Boice JD, Fuller CD, Thompson RF, Trister AD, Formenti SC, Barcellos-Hoff MH, Jones J, Dharmarajan KV, Zietman AL, Coleman CN. Enhancing Career Paths for Tomorrow's Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):52-63. PMID: 31128144.
      View in: PubMed
    6. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 05 22; 7(1):131. PMID: 31113486.
      View in: PubMed
    7. Jung SY, Malhotra P, Nguyen KC, Salzman D, Qi Y, Pak EH, King J, Vlashi E, Ann D, Weidhaas JB. The KRAS-variant and its impact on normal breast epithelial cell biology. Cell Death Differ. 2019 Dec; 26(12):2568-2576. PMID: 30932013.
      View in: PubMed
    8. Malhotra P, Read GH, Weidhaas JB. Breast Cancer and miR-SNPs: The Importance of miR Germ-Line Genetics. Noncoding RNA. 2019 Mar 20; 5(1). PMID: 30897768.
      View in: PubMed
    9. Rahimy E, Weidhaas J, Wei W, Lannin D, Horowitz N, Higgins S, Wilson LD, Knowlton C, Moran MS, Young MR, Killelea B, Chagpar A, Yeboa DN, Zelterman D, Evans S. Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation. Pract Radiat Oncol. 2019 May; 9(3):e257-e265. PMID: 30796975.
      View in: PubMed
    10. Yuan Y, Weidhaas JB. Functional microRNA binding site variants. Mol Oncol. 2019 01; 13(1):4-8. PMID: 30536617.
      View in: PubMed
    11. Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Hum Pathol. 2018 06; 76:133-140. PMID: 29518404.
      View in: PubMed
    12. Shaverdian N, Wang X, Hegde JV, Aledia C, Weidhaas JB, Steinberg ML, McCloskey SA. The patient's perspective on breast radiotherapy: Initial fears and expectations versus reality. Cancer. 2018 04 15; 124(8):1673-1681. PMID: 29479673.
      View in: PubMed
    13. Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA. Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. Clin Breast Cancer. 2018 04; 18(2):e205-e218. PMID: 29050918.
      View in: PubMed
    14. McVeigh TP, Mulligan RJ, McVeigh UM, Owens PW, Miller N, Bell M, Sebag F, Guerin C, Quill DS, Weidhaas JB, Kerin MJ, Lowery AJ. Investigating the association of rs2910164 with cancer predisposition in an Irish cohort. Endocr Connect. 2017 Nov; 6(8):614-624. PMID: 28899898.
      View in: PubMed
    15. Mehta AK, Hua K, Whipple W, Nguyen MT, Liu CT, Haybaeck J, Weidhaas J, Settleman J, Singh A. Regulation of autophagy, NF-?B signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Sci Signal. 2017 Sep 12; 10(496). PMID: 28900044.
      View in: PubMed
    16. Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA. Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. Breast Cancer Res Treat. 2017 Nov; 166(1):145-156. PMID: 28702891.
      View in: PubMed
    17. Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY. Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):274-284. PMID: 28964588.
      View in: PubMed
    18. Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Apr 01; 3(4):483-491. PMID: 28006059.
      View in: PubMed
    19. Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB. Erratum: The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding RNA 2016, 2, 9. Noncoding RNA. 2016 09 30; 2(4). PMID: 29657269.
      View in: PubMed
    20. Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB. The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Noncoding RNA. 2016 Sep 21; 2(3). PMID: 29657267.
      View in: PubMed
    21. Nemec AA, Bush KB, Towle-Weicksel JB, Taylor BF, Schulz V, Weidhaas JB, Tuck DP, Sweasy JB. Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-Associated R438W DNA Polymerase Lambda Protein. Mol Cancer Res. 2016 11; 14(11):1068-1077. PMID: 27621267.
      View in: PubMed
    22. Metheetrairut C, Adams BD, Nallur S, Weidhaas JB, Slack FJ. cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation. Oncogene. 2017 01 26; 36(4):512-524. PMID: 27321180.
      View in: PubMed
    23. Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ, Weidhaas JB. miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage. Nat Commun. 2016 Mar 21; 7:10954. PMID: 26996824.
      View in: PubMed
    24. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2016 Jan; 48(1):101. PMID: 26711112.
      View in: PubMed
    25. McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB. Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle. 2015; 14(13):2091-9. PMID: 25961464.
      View in: PubMed
    26. Chen J, Morrical MD, Donigan KA, Weidhaas JB, Sweasy JB, Averill AM, Tomczak JA, Morrical SW. Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase. Nucleic Acids Res. 2015 Jan; 43(2):1098-111. PMID: 25539919.
      View in: PubMed
    27. Nath SK, Chen ZJ, Rowe BP, Blitzblau RC, Aneja S, Grube BJ, Horowitz NR, Weidhaas JB. A PHASE II TRIAL OF BALLOON-CATHETER PARTIAL BREAST BRACHYTHERAPY OPTIMIZATION IN THE TREATMENT OF STAGE 0, I AND IIA BREAST CARCINOMA. J Radiat Oncol. 2014 Dec; 3(4):371-378. PMID: 25485042.
      View in: PubMed
    28. Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res. 2014 Sep 01; 20(17):4499-4510. PMID: 25183481.
      View in: PubMed
    29. Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2014 Nov; 25(11):2230-6. PMID: 25081901.
      View in: PubMed
    30. Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan CA, Lindner R, Curran C, Lezon-Geyda K, McVeigh T, Harris L, Newell J, Kerin MJ, Wood M, Miller N, Weidhaas JB. A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer. BMC Cancer. 2014 Jun 10; 14:421. PMID: 24915755.
      View in: PubMed
    31. Chen X, Paranjape T, Stahlhut C, McVeigh T, Keane F, Nallur S, Miller N, Kerin M, Deng Y, Yao X, Zhao H, Weidhaas JB, Slack FJ. Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. Oncogene. 2015 Apr 16; 34(16):2125-37. PMID: 24909162.
      View in: PubMed
    32. Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W. Radiation therapy oncology group gynecologic oncology working group: comprehensive results. Int J Gynecol Cancer. 2014 Jun; 24(5):956-62. PMID: 24819663.
      View in: PubMed
    33. Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. PLoS One. 2014; 9(4):e94167. PMID: 24732316.
      View in: PubMed
    34. Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle. 2014; 13(6):1030-40. PMID: 24552817.
      View in: PubMed
    35. Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park CC, Weidhaas JB, Zietman AL, Steinberg M. Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. Int J Radiat Oncol Biol Phys. 2014 Jan 01; 88(1):11-7. PMID: 24246724.
      View in: PubMed
    36. Kunos CA, Winter K, Dicker AP, Small W, Abdul-Karim FW, Dawson D, Jhingran A, Valicenti R, Weidhaas JB, Gaffney DK. Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. Int J Gynecol Cancer. 2013 May; 23(4):615-21. PMID: 23552804.
      View in: PubMed
    37. Doll CM, Winter K, Gaffney DK, Ryu JK, Jhingran A, Dicker AP, Weidhaas JB, Miller BE, Magliocco AM. COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. Int J Gynecol Cancer. 2013 Jan; 23(1):176-83. PMID: 23221733.
      View in: PubMed
    38. Preskill C, Weidhaas JB. SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers. Crit Rev Oncog. 2013; 18(4):327-40. PMID: 23614619.
      View in: PubMed
    39. Salzman DW, Weidhaas JB. SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther. 2013 Jan; 137(1):55-63. PMID: 22964086.
      View in: PubMed
    40. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A. 2012 Jun 26; 109(26):E1695-704. PMID: 22685206.
      View in: PubMed
    41. Moran MS, Ma S, Jagsi R, Yang TJ, Higgins SA, Weidhaas JB, Wilson LD, Lloyd S, Peschel R, Gaudreau B, Rockwell S. A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):40-6. PMID: 22658441.
      View in: PubMed
    42. Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLoS One. 2012; 7(5):e37891. PMID: 22662244.
      View in: PubMed
    43. Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS. A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. EMBO Mol Med. 2012 Mar; 4(3):206-17. PMID: 22307873.
      View in: PubMed
    44. Kundu ST, Nallur S, Paranjape T, Boeke M, Weidhaas JB, Slack FJ. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Cell Cycle. 2012 Jan 15; 11(2):361-6. PMID: 22189714.
      View in: PubMed
    45. Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 2012 Oct 18; 31(42):4559-66. PMID: 22139083.
      View in: PubMed
    46. Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biol Ther. 2011 Nov 15; 12(10):908-14. PMID: 22027557.
      View in: PubMed
    47. Weidhaas JB, Slack FJ. KRAS rs61764370 in Epithelial Ovarian Cancer-Letter. Clin Cancer Res. 2011 Oct 15; 17(20):6600; author reply 6601. PMID: 22003074.
      View in: PubMed
    48. Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res. 2011 Dec 15; 17(24):7723-31. PMID: 21994416.
      View in: PubMed
    49. Salzman DW, Weidhaas JB. miRNAs in the spotlight: Making 'silent' mutations speak up. Nat Med. 2011 Aug 04; 17(8):934-5. PMID: 21818091.
      View in: PubMed
    50. Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle. 2011 Jun 01; 10(11):1845-52. PMID: 21543894.
      View in: PubMed
    51. Weidhaas JB, Kirsch DG. The Holman Research Pathway in radiation oncology. Int J Radiat Oncol Biol Phys. 2011 Jun 01; 80(2):321-3. PMID: 21549248.
      View in: PubMed
    52. Elkin EB, Klem ML, Gonzales AM, Ishill NM, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Constine LS, Myrehaug S, Yahalom J. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol. 2011 Jun 20; 29(18):2466-73. PMID: 21576642.
      View in: PubMed
    53. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011 Jun; 19(6):1116-22. PMID: 21427705.
      View in: PubMed
    54. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol. 2011 Apr; 12(4):377-86. PMID: 21435948.
      View in: PubMed
    55. Chan E, Prado DE, Weidhaas JB. Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends Mol Med. 2011 May; 17(5):235-43. PMID: 21354374.
      View in: PubMed
    56. Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle. 2011 Jan 01; 10(1):90-9. PMID: 21191178.
      View in: PubMed
    57. Blitzblau RC, Weidhaas JB. MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk. Mol Diagn Ther. 2010 Dec 01; 14(6):335-42. PMID: 21275451.
      View in: PubMed
    58. Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ. A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene. 2011 Mar 31; 30(13):1542-50. PMID: 21119596.
      View in: PubMed
    59. Leaderer D, Hoffman AE, Zheng T, Fu A, Weidhaas J, Paranjape T, Zhu Y. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int J Mol Epidemiol Genet. 2011 Jan 01; 2(1):9-18. PMID: 21552306.
      View in: PubMed
    60. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Brook-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010 Oct; 42(10):880-4. PMID: 20852633.
      View in: PubMed
    61. Pelletier C, Weidhaas JB. MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Rev Mol Diagn. 2010 Sep; 10(6):817-29. PMID: 20843204.
      View in: PubMed
    62. Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat. 2011 Jul; 128(1):79-84. PMID: 20676756.
      View in: PubMed
    63. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 2010 Aug 15; 70(16):6509-15. PMID: 20647319.
      View in: PubMed
    64. Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol. 2010 Sep; 118(3):251-7. PMID: 20542546.
      View in: PubMed
    65. Weidhaas J. Using microRNAs to understand cancer biology. Lancet Oncol. 2010 Feb; 11(2):106-7. PMID: 20022811.
      View in: PubMed
    66. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2010 Mar 18; 29(11):1580-7. PMID: 19966857.
      View in: PubMed
    67. Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: tools for cancer diagnostics. Gut. 2009 Nov; 58(11):1546-54. PMID: 19834118.
      View in: PubMed
    68. Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res. 2009 Jul 15; 69(14):5970-7. PMID: 19567675.
      View in: PubMed
    69. Weidhaas JB, Li SX, Winter K, Ryu J, Jhingran A, Miller B, Dicker AP, Gaffney D. Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128. Clin Cancer Res. 2009 Jun 15; 15(12):4199-206. PMID: 19509178.
      View in: PubMed
    70. Kato M, Paranjape T, Müller RU, Ullrich R, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 2009 Jun 25; 28(25):2419-24. PMID: 19421141.
      View in: PubMed
    71. Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung GG, DiGiovanna MP, Miller K, Higgins SA, Weidhaas J, Harris L, Tavassoli FA, Lannin DR. Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol. 2009 Mar; 16(3):697-702. PMID: 19132447.
      View in: PubMed
    72. Slack FJ, Weidhaas JB. MicroRNA in cancer prognosis. N Engl J Med. 2008 Dec 18; 359(25):2720-2. PMID: 19092157.
      View in: PubMed
    73. Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics. Oncogene. 2008 Dec; 27 Suppl 2:S52-7. PMID: 19956180.
      View in: PubMed
    74. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008 Oct 15; 68(20):8535-40. PMID: 18922928.
      View in: PubMed
    75. Grube BJ, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, Digiovanna MP, Chung G, Abu-Khalaf MM, Miller KD, Higgins SA, Philpotts L, Tavassoli FA, Lannin DR. Breast sentinel lymph node dissection before preoperative chemotherapy. Arch Surg. 2008 Jul; 143(7):692-9; discussion 699-700. PMID: 18645113.
      View in: PubMed
    76. Yu JB, Wilson LD, Dasgupta T, Castrucci WA, Weidhaas JB. Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy: analysis of the NCI Surveillance, Epidemiology, and End Results database. Cancer. 2008 Jul 01; 113(1):38-47. PMID: 18442108.
      View in: PubMed
    77. Babar IA, Slack FJ, Weidhaas JB. miRNA modulation of the cellular stress response. Future Oncol. 2008 Apr; 4(2):289-98. PMID: 18407740.
      View in: PubMed
    78. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008 Mar 15; 7(6):759-64. PMID: 18344688.
      View in: PubMed
    79. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007 Dec 01; 67(23):11111-6. PMID: 18056433.
      View in: PubMed
    80. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006 Dec 20; 24(36):5652-7. PMID: 17116942.
      View in: PubMed
    81. Weidhaas JB, Eisenmann DM, Holub JM, Nallur SV. A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans. Cancer Res. 2006 Nov 01; 66(21):10434-8. PMID: 17079464.
      View in: PubMed
    82. Weidhaas JB, Eisenmann DM, Holub JM, Nallur SV. A Caenorhabditis elegans tissue model of radiation-induced reproductive cell death. Proc Natl Acad Sci U S A. 2006 Jun 27; 103(26):9946-51. PMID: 16788064.
      View in: PubMed
    83. Slack FJ, Weidhaas JB. MicroRNAs as a potential magic bullet in cancer. Future Oncol. 2006 Feb; 2(1):73-82. PMID: 16556074.
      View in: PubMed